Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research
Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research Numinus (NUMI) received Health
March 9, 2022
Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research Numinus (NUMI) received Health
Braxia Scientific Reports Q3 2022 Financial Results; Company Leads in Psychedelic Research, Access and Therapist
Red Light Holland Reports Fiscal Third Quarter Results Red Light Holland (TRIP) reported quarterly financial results
Optimi Health Upgrades Trading to the OTCQX Best Market Optimi Health (OPTI) upgraded its common shares
Novamind Reports Fiscal Q2 2022 Financial Results and Operating Highlights Novamind (NM) reported quarterly financial
Incannex Completes Listing of American Depositary Shares on Nasdaq; Rings Nasdaq Closing Bell Incannex Healthcare
COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business
Vancouver discovery will make ‘Magic Mushroom’ mental health care cheaper Producing psilocybin is wildly expensive
Filament Health and ATMA Journey Centers Announce Licensing Agreement Filament Health (FH) will license its natural
Biomind Labs Announces Upgrade to the OTCQB® Venture Market in the United States Biomind Labs
Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in
Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study Entheon Biomedical (ENBI) initiated a ketamine
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation PharmaTher (PHRM) was granted a US patent
Field Trip Health Ltd. Reports Third Fiscal Quarter 2022 Financial Results and Provides Business Update
Enveric Biosciences Shares Tumble Premarket on Public Offering ENVB Enveric Biosciences’ (ENBI) plummeted 45% this
Ehave, Inc. Expands Its KetaDASH Brand And Begins Producing Revenue With The Purchase Of California
Optimi Health Dealer’s License Granted by Health Canada Optimi Health (OPTI) received a Dealer’s License from
Ketamine Media Launches Industry-Leading Psychedelic Therapy Network Ketamine Media launched Psychedelic Therapy Network, a digital
Entheon Biomedical Announces the Approval of DMT Clinical Trial Entheon Biomedical (ENBI) received approval for a
Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3
Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp.
Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial Numinus Wellness (NUMI)
Psygen Receives Dealer’s Licence from Health Canada Psygen Industries Ltd. is building Canada’s first manufacturing
Ketamine One Begins Trading On The OTCQB Marketplace On January 12, 2022 Ketamine One (MEDI) began